Barron's

Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with ...

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With Ig…

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive data from a pre-specified Week 36 interim ...

Vertex to Participate in Upcoming March Investor Conferences

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences.

Vertex Innovations Names Jason Hughes VP of Mission Critical Operations

Hughes to lead hyperscale data center operations, business development, and training across Vertex’s fastest-growing division DENVER, March 03, 2026 (GLOBE NEWSWIRE) -- Vertex Innovations, a national ...
Barron's

Vertex Resource Group Ltd.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Vertex Reports Fourth Quarter and Full Year 2025 Financial Results

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the fourth quarter and full year ended December 31, 2025, and provided its full year 2026 financial ...
The Boston Globe

Vertex’s CRISPR treatment for sickle cell disease hits unexpected roadblock

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Vertex executives warned that Casgevy, its ...
STAT

Vertex’s CRISPR treatment for sickle cell disease hits unexpected roadblock

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...
Business Wire

Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, after the financial ...
CSOonline

Google Vertex AI security permissions could amplify insider threats

A new way to escalate privileges inside Google’s Vertex AI highlights a broader problem: Enterprises have a level of trust in AI offerings that needs to be fundamentally reexamined. The finding of ...
Nasdaq

Where Will Vertex Pharmaceuticals Be in 5 Years

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...